Supreme Court | GenomeWeb

Supreme Court

The case is being framed as either upholding a strong patent regime or dealing a blow to US-based manufacturing as part of the global supply chain.

Arti Rai and Colleen Chien are studying whether the Supreme Court's decisions in Mayo v Prometheus and Bilski v Kappos have had a negative impact on diagnostics innovation.

NEW YORK (GenomeWeb) – While industry observers might disagree about whether GeneDx's decision to apply for inter partes review (IPR) of 11 patents held by Myriad Genetics will work in its favor, they generally concur that it is a quicker and less costly strategy than litigation.

This article has been updated to include a statement from Myriad Genetics.

At the San Antonio Breast Cancer Symposium last week, Myriad Genetics presented new data on its myRisk Hereditary Cancer panel, which the firm believes will help it convince physicians, patients, and payors of the advantages of multi-gene panels over single disease testing.

Industry reactions to the US Supreme Court's decision to invalidate patents on isolated gene sequences were immediate and ranged from elation to disappointment.

Women with a family history of breast and ovarian cancer who are interested in getting genetically tested to gauge whether they have a heightened risk for the diseases should speak to a genetic counselor before getting tested, patient groups are advising their members.

NEW YORK (GenomeWeb News) – The US Supreme Court today unanimously ruled that human genes are not patentable, but synthetic DNA, or cDNA, is patent eligible because it does not occur naturally.

WASHINGTON (GenomeWeb News) – US Supreme Court justices today heard arguments in favor of and against the patent eligibility of genes isolated from the body, a practice that the US Patent and Trademark Office has enabled for more than three decades.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.